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Head and neck squamous cell carcinomas are aggressive tumors that often present at advanced stage in difficult-to-biopsy
regions of the head and neck. With the rapid move to analyze circulating tumor DNA (ctDNA) to either detect cancer or moni-
tor disease progression and response to therapy, we have designed this article as a primer to understand the recent studies
that support a transition to use these circulating biomarkers as a part of routine clinical care. Whereas some technical chal-
lenges still need to be overcome, the utility of ctDNA in cancer care is already evident from these early studies. Therefore, it is
critical to understand recent advances in this area as well as emerging questions that need to be addressed as these bio-
markers move closer to enhancing routine clinical care paradigms.
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INTRODUCTION
Head and neck cancer is one of the leading causes of
cancer deaths worldwide.1 Head and neck squamous cell
carcinoma (HNSCC) comprises the vast array of tumors,
including those arising from the nose, nasal cavity, para-
nasal sinuses, oral cavity, pharynx, and larynx. Within
the last several decades, the rising incidence of oropha-
ryngeal cancer, particularly in the younger population,
has been attributed to high-risk human papillomavirus
(HPV) subtypes2 as well as potential hereditary genetic
factors.3,4 The detection of primary HNSCC and recur-
rence is challenging due to the nature of the anatomy
involved. Diagnosis is often delayed and requires clinical
examination, imaging, and microscopic tissue analysis,
all of which can be significantly hindered by the location
of the tumors. There is significant interest in the develop-
ment of a biomarker surveillance tool that might allow
for earlier diagnosis and bypass the need to undergo a
surgical procedure. In this review article, we performed a
systematic review of the literature, focusing on the devel-
opment of serum-based biomarkers, particularly circulat-
ing tumor DNA (ctDNA), in HNSCC. We included a
number of current articles that we believe will influence
the future research of liquid biomarkers in HNSCC. As
such, our systematic literature search included articles
published through September 9, 2018, and was performed
using MEDLINE, EMBASE, and Google Scholar for rele-
vant articles. Non-peer–reviewed articles, letters to the
editor, commentaries, and editorials were excluded. All
review authors independently screened titles and
abstracts of potential studies to assess validity (Table I).
Subsequently, the full text of all eligible studies was inde-
pendently reviewed by three review authors (P.L.S., J.R.B.,
J.C.B.) who evaluated the potential articles for inclusion.
Background to Serum-Based Biomarkers
As defined by the Biomarkers Definitions Working
Group, a biomarker is “a characteristic that is objectively
measured and evaluated as an indicator of normal biolog-
ical processes, pathogenic processes, or pharmacologic
responses to a therapeutic intervention.”5 Biomarkers
may offer insight into diseases in many contexts, includ-
ing screening and diagnosis, yielding predictive informa-
tion to alter therapy and therapy monitoring or serving
as a prognostic tool by risk stratification. All of these
roles point to the central role of validating a biomarker
with a specific clinical endpoint,5 which may be signifi-
cantly different depending on the point in disease pro-
gression (Fig. 1).
The term circulating biomarkers encompasses an
array of analytes including proteins, circulating tumor
cells (CTCs), ctDNA, and tumor exosomes. These circulat-
ing biomarkers have been explored in numerous cancers
and situations, including screening, prognostication, eval-
uating response to therapy, and predicting response to
novel therapeutics. Determining prognosis was one of the
initial areas in which circulating biomarkers were
explored. In nonmetastatic colorectal cancer, for example,
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both increased baseline ctDNA presurgery and persis-
tently detectable ctDNA postoperatively have been associ-
ated with poor prognosis.6,7 Enumeration of CTCs in
breast cancer has been found to be an independent pre-
dictor of survival in metastatic breast cancer. Interest-
ingly, the number of CTCs after 1 month of therapy has
been validated to predict survival. Importantly, this is
prior to when traditional radiographic imaging response
would be expected.8 Trials have not demonstrated a bene-
fit to early change in therapy based on CTCs, emphasiz-
ing the dual importance of validated tumor biomarkers
and effective therapeutics. In addition, research into the
use of CTCs in HNSCC have been limited by small
cohorts, heterogeneous cancer subtypes, and nonstandar-
dized detection methods. Therefore, this requires further
validation and study.9,10 Ultimately, comparative work in
metastatic breast cancer has suggested that ctDNA is a
more sensitive biomarker than enumeration of CTCs, and
their dynamics may better reflect tumor response to
therapy.11
Circulating tumor biomarkers have begun to make a
foray into the clinic with the era of precision oncology and
targeted therapeutics. This has been most notable in lung
adenocarcinoma; studies have demonstrated a ctDNA-
based assay to detect targetable mutations and resistance
pathways (i.e., EGFR) in the circulation, potentially
avoiding biopsy.12–14 Genotyping of plasma ctDNA has
demonstrated a sensitivity of 74% to 86.3% (specificity
96.5%–100%) for EGFR exon 19/L858R mutants. Even
more compelling is that the mutation most frequently
responsible for the loss of EGFR-directed therapy,
T790 M, was able to be accurately detected with a
TABLE I.




Chuang et al 2008 59 Quantitative measurement of HPV-16
DNA in saliva can potentially assist
in surveillance and early detection
of recurrence. Patients with the
presence of HPV- 16 DNA in
salivary rinses are at significant risk
for recurrence.
Cheng et al 2009 15 ctDNA plasma levels in cancer
patients during radiation therapy
are dynamic throughout the course
of treatment and may provide
real-time assessments of respones
to chemotherapy and radiotherapy
Ahn et al 2014 93 Combined pretreatment plasma and
saliva can increase the utility of




Wang et al 2015 47 Sensitivity of HPV-16 DNA detection
varies greatly depending on tumor
location: saliva is more often
enriched for tumor DNA from the
oral cavity, but plasma is more
often enriched for tumor DNA from
the other sites.
Dahlstrom et al 2015 262 Pretreatment serum HPV DNA is
associated with both higher N
category and overall disease stae
but it does not seem to serve as a
marker for disease recurrence
among patients with oropharyngeal
cancer.
ctDNA = circulating tumor DNA; HPV = human papillomavirus.
Fig. 1. Circulating biomarkers may have different goals depending on clinical course and intent of the assay. The schematic represents a stan-
dardized long-term clinical course for a patient with HNSCC. Treatment modalities are indicated on the top, whereas potential uses of circulat-
ing biomarkers are defined on the bottom. In the case of ctDNA assays, endpoints focused on active surveillance of premalignant patients
may require a broad ability to detect diverse genetic alterations in order to detect cancers with unknown alterations, whereas active surveil-
lance of patients with a sequenced primary tumor may only require monitoring of a few established alterations (e.g., patient-specific TP53
mutations). Similarly, analysis of genetic changes during clonal outgrowth may also benefit from broad spectrum assays to detect unknown
alterations, whereas assays monitoring for treatment-driven selection of therapy-resistant clones (e.g., therapy-driven mutations) may be able
to focus on monitoring of highly recurrent mechanisms of resistance for a specific therapeutic. ctDNA = circulating tumor DNA; HNSCC = head
and neck squamous cell carcinoma. [Color figure can be viewed in the online issue, which is available at www.laryngoscope.com.]
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sensitivity of 70.3% to 77% (specificity 63%–100%).12,13
Although this could detect roughly 70% of EGFR muta-
tions, given the sensitivity, a tumor biopsy may still be
warranted in patients with a negative result. Past studies
have repeatedly documented that patients with target-
able mutations treated with targeted therapies have
superior PFS compared to those treated with conven-
tional chemotherapy.15,16 Hence, these ctDNA biomarkers
are one step closer to achieving the ultimate goal of bio-
marker development: altering clinical endpoints and
improving outcomes. Based on these data, the FDA
approved the Cobras EGFR mutation test as first ctDNA
biomarker assay for use in clinical practice. Use of similar
liquid biopsies is being incorporated into societal guide-
lines for patients with advanced non-small cell lung can-
cer.17 Each of the circulating tumor biomarkers
(e.g., CTCs, ctDNA, exosomes, proteins, antibodies) is dis-
tinct with complimentary roles; for this review, we will
focus on ctDNA and its potential application in HNSCC.
Introduction to ctDNA
The concept of ccfDNA (circulating cell-free DNA)
correlation with human disease was first introduced in
1948,18 and increased concentrations of ccfDNA in the cir-
culation of cancer patients was first noted in 1977.19 Sub-
sequently, evidence that cfDNA is released into the
circulation by tumors (termed ctDNA) was found when
tumor-specific aberrations were noted in cfDNA, includ-
ing tumor suppressor and oncogene mutations, microsat-
ellite instability, and DNA methylation.20–23
A variety of biological fluids, including blood, lymph,
urine, saliva, and cerebrospinal fluid, contain ccfDNA. In
the blood, ccfDNA is predominately short, double-stranded
fragments of nuclear and mitochondrial DNA of approxi-
mately 160 to 180 base pairs length.24 The primary mecha-
nism of DNA release into circulation continues to be
somewhat debated; however, the literature suggests that it
is a result of apoptosis and possibly also necrosis and viable
tumor cell secretion.25,26 Lo et al. used whole genome
sequencing of plasma DNA of pregnant women to demon-
strate that plasma DNA molecules showed a predictable
fragmentation pattern consistent with nuclease-cleaved
nucleosomes, implicating apoptosis.27 Size distribution of
cfDNA in healthy individuals and cancer patients also con-
firms this, revealing an enrichment of size fragments of sin-
gle or multiples of nucleoprotein complexes, and suggested
that the main driver of release may be apoptosis.28 Under-
hill et al. demonstrated that ctDNA fragments may be
shorter (approximately 130 base pairs) than ccfDNA derived
from noncancer cells.29
Through assessment of tumor genetic aberrations in
ccfDNA, studies have estimated that the fraction of
ctDNA within the total ccfDNA in cancer patients is
approximately 10%.7,30 Levels of ccfDNA can be influ-
enced by increased production as well as stability to circu-
lating nucleases and clearance in the kidney, liver, and
spleen. Real-time assessment of a cancer may be possible
from ctDNA because the half-life of ccfDNA ranges from
about 15 minutes to several hours.31–36 Some reports
indicate that the growth rate of the tumor leads to a
higher degree of necrosis, corresponding to an increase in
circulating tumor DNA. Diehl et al. suggested that DNA
fragments found in the circulation are derived from
necrotic neoplastic cells that had been engulfed by
macrophages.37
Studies to Date of ctDNA in Head and Neck
Cancer
The use of ctDNA in patients with HNSCC is less
established than in patients with other cancers such as
colorectal, breast, and lung. Nevertheless, research has
demonstrated that it is indeed viable, and the potential
for applications is vast.32–36 The most-studied ctDNA bio-
marker in HNSCC is HPV-related (HPV+) malignancies
because HPV and its downstream protein effectors pre-
sent as convenient biomarkers for detection in the circula-
tion.38 Using real-time polymerase chain reaction
(RT-PCR) amplification, a minute amount of HPV-16
DNA has been shown to be detectable in saliva and
plasma samples. This study in question included
93 patients with oropharyngeal or unknown primary
squamous cell carcinoma with known HPV status and a
complete set of pre- and posttreatment plasma or saliva
samples.32 One study of patients with various stages on
HNSCC demonstrated that tumor DNA, as defined by
either somatic mutations or HPV incorporation, is detect-
able in 96% of patients when both plasma and saliva are
sampled.33 When considered by body fluid type, the sensi-
tivity of detection varied greatly depending on tumor
location. ctDNA was detectable in the saliva samples of
between 47% and 100% of patients, with the highest
detection in tumors of the oral cavity (100%). Plasma sen-
sitivity was similarly as variable, ranging from 80% to
100%, highest in the hypopharynx (100%) (Table II).
These complimentary detection rates emphasize the
importance of considering which body fluid(s) to evaluate
in the development of tests. Interestingly, even when
saliva and plasma were combined, tumor DNA was
detected in just 86% of HPV+ patients.33
Preliminary research has also suggested that the
presence or absence of HPV-16 DNA is a feasible means
of surveilling disease posttreatment HPV-16 DNA status
in saliva.32,34 The detection of HPV-16 DNA in salivary
rinses occurred on average over 3 months before clinical
detection of recurrence.34 In this particularly study,
59 patients were included who presented with histopatho-
logically confirmed HNSCC, had one or more posttreat-
ment salivary sample, and had been previously treated
with curative intent. However, only four of these patients
had recurrent HPV+ tumors, of which two had detectible
HPV-16 in surveillance salivary rinses. A larger study
demonstrated that, when combining plasma and salivary
surveillance testing, persistence of HPV-16 DNA post-
treatment was 69.5% sensitive and 90% specific for pre-
dicting recurrence within 3 years32 (Table II). However,
due to the excellent outcomes of HPV-related oropharyn-
geal cancer, these findings were based on a small number
of recurrences. Not all studies have found ctDNA to have
clinical utility in predicting disease recurrence in
HNSCC.35 A study with a different approach assessed the
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use of pretreatment rather than posttreatment ctDNA as
a predictor for disease recurrence in oropharyngeal can-
cer. Pretreatment HPV DNA in the serum was associated
with a higher nodal category and overall stage; however,
it was not associated with differences in progression-free
survival.35 This study had a recurrence rate of just 13%
and thus may not have been powered to detect significant
associations. Studies to date have lacked the statistical
power to validate the role of ctDNA in the detection of
recurrence. Confirmation and validation of a candidate
biomarker is one of the most challenging issues in trans-
lational science. It is a time- and labor-intensive process
requiring multiple patient cohorts. Significant literature
has been published outlining processes for appropriate
clinical biomarker discovery, including independent dis-
covery and validation cohorts prior to clinical evaluation
for utility. Clinical evaluation may take one of many
designs, including prospective clinical trials in which the
test may or may not direct management. Design of a pro-
spective biomarker validation clinical trial requires close
collaboration with colleagues in bioinformatics and statis-
ticians, but the sample size is dependent in part on the
role of the test. If the biomarker is designed to detect dis-
ease recurrence, an ample number of patients treated
uniformly must be enrolled to detect an appropriate num-
ber of reoccurrences to make appropriate conclusions on
the biomarker test characteristics. Even more challeng-
ing, in order to define the clinical utility of a proposed bio-
marker, a study (often as a follow-up) must be designed
wherein the results of the biomarker change clinical
management.39–41 In the situation of HPV-related
HNSCC, the recurrence rate is so low that a large cohort
is necessary to statistically determine the test character-
istics of HPV ctDNA (sensitivity, specificity, area under
the curve [AUC]). Furthermore, to solidify its role in clini-
cal practice, a study would need to be designed in which
observation would be changed based on detection of HPV
ctDNA. For example, if ctDNA was detected, posttreat-
ment patients would be randomized to more intensive
surveillance or adjuvant chemotherapy and monitored for
improvement in survival. Therefore, although ctDNA
may indeed be a potential adjunct to provide less invasive
monitoring for recurrent HNSCC, it requires further
large prospective studies.
Another application of ctDNA in HNSCC is in asses-
sing real-time responses to chemotherapy and radiother-
apy. A study looking at the ctDNA plasma levels in
cancer patients during radiation therapy found that con-
centrations were dynamic throughout the course of treat-
ment. The patients studied had various types of cancer,
but more than half of these were localized to the head
and neck. In most of the patients, the levels of ctDNA
underwent an initial, transient rise at the initiation of
therapy, after which they declined.42 However, this study
was limited both by the variety of malignancies included
and by the numerous different treatment modalities.
Other studies have demonstrated similar results in
patients undergoing radiation and chemotherapy in
which there is an initial rise in concentration followed by
a slow decline back to pretreatment level.43–46 Further
research may build upon this foundation to determine
whether these dynamic levels of ctDNA correlate with
treatment efficacy.
The final application of ctDNA that is currently
under investigation in HNSCC is its use in metastatic
disease. As aforementioned, research in other malignan-
cies has demonstrated the ability to utilize ctDNA
to predict response to chemotherapeutic agents.11 It
allows for a much less invasive means to select patients
who these therapies may benefit. Similarly in lung
adenocarcinoma, ctDNA has been able to identify target-
able mutations (EGFR, ALK, ROS-1, BRAF) in which
targeted therapies are beneficial.14–17 Unfortunately,
unlike lung adenocarcinoma, to date no driver muta-
tions have been identified in HNSCC, and no mutations
have been isolated predictive of response to systemic
therapy. Given data regarding the association of tumor
mutational burden as assessed by whole exome sequenc-
ing in tumor samples and response to immunotherapy,47
ongoing research is aiming to define whether this infor-
mation may be assessed from ctDNA. For example,
given the recent emergence of immunotherapies in
HNSCC,48 one recent exploratory study using a commer-
cial next generation sequencing (NGS) ctDNA assay
investigated patients with unresectable or metastatic
disease who were undergoing checkpoint inhibitor-based
immunotherapy. Thirteen percent of the patients in this
study had HNSCC. This study suggested that higher
alteration number on ctDNA liquid biopsy is associated
with a significantly improved response to checkpoint
TABLE II.
Studies of Circulating Tumor DNA in Head and Neck Cancer.








Oral cavity 100% 80% 100%
Oropharynx 47% 91% 91%
Larynx 70% 86% 100%
Hypopharynx 67% 100% 100%
HPV+ 40% 86% 86%
Total 76% 87% 96%








Saliva 20 50% 100%
Ahn et al., 2014† Saliva 72 19% 97%




ctDNA detection rates from three of the first HNSCC studies are
summarized.
*Testing characteristics for surveillance HPV DNA association with
tumor recurrence.
†Testing characteristics for posttreatment HPV DNA association with
tumor recurrence within 3 years.
ctDNA = circulating tumor DNA; HNSCC = head and neck squamous
cell carcinoma; HPV+ = human papillomavirus-related.
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inhibitor-based immunotherapy.49 This is consistent
with findings from primary tissue biopsies. Despite the
limitations inherent to a study with a smaller HNSCC
population, the literature suggests ctDNA may have a
role in predicting those metastatic and recurrent
patients for whom the prospective therapeutic benefit of
immunotherapy is greatest. With further validation,
ctDNA could assist in limiting the number of patients
who are unnecessarily exposed to the adverse effects of
these therapies.
In addition to its use in HPV+ malignancies, bio-
markers have also been studied in epstein barr virus
(EBV) related nasopharyngeal carcinoma (NPC) as a
means to assess treatment response, prognosticate out-
come, and screen. Several studies have shown that cir-
culating EBV DNA is detectable in both the plasma and
the serum of patients with NPC.50,51 In one study,
107 patients with stage IIB-IV NPC had their plasma
EBV DNA load tested before, at the midpoint of, and
after the culmination of chemoradiation. Of these, there
35 patients failed therapy in whom there was detect-
able midpoint DNA in 74%. Detectable midpoint EBV
DNA was found to be prognostic of treatment failure
and was more predictive of outcomes than was tumor
stage.46 Another prospective study found that patients
with NPC who recurred or metastasized had higher
pretreatment plasma or serum EBV DNA concentra-
tions than those who did not. Within the first year after
treatment, quantification of plasma EBV DNA was a
better adverse prognosticator than disease stage.52
Finally, EBV has been studied as a means to screen
20 thousand asymptomatic, ethnically Chinese, middle-
aged male patients for NPC. Of these, 309 tested per-
sistently positive, and 34 went on to have confirmed
NPC; the sensitivity and specificity of the presence of
EBV DNA in plasma was found to be 97.1% and 98.6%,
respectively. These patients were detected at earlier
stages had better progression-free survival than those
in previously studied cohorts.53 This study is limited
insofar that it had a short follow-up time and thus was
unable to evaluate the impact on long-term outcomes,
particularly in the setting of the high rate of survival
in NPC.54 Additionally, the high number needed to
screen, and the expenses associated with screening
necessitate further evaluation of its cost-effectiveness.
Despite these potentially promising applications, the
Fig. 2. Challenges in optimizing a ctDNA panel based on the diversity of HNSCC molecular alterations. (A) Top 10 most recurrent molecular
alterations in primary untreated disease as defined by the HNSCC TCGA sequencing set (N = 530). Several of these genes are tumor suppres-
sors from long, multi-exon genes. (B) Top 10 most recurrent copy number alterations from HNSCC TCGA data and the total genes in each
region are indicated. (C) Representation of regions that are required to be covered if ctDNA analysis focuses on tumor suppressors using
FBXW7 schematic as an example (all exons would need coverage based on the low recurrence of hot spot alterations). Boxes represent
exons, with blue boxes representing untranslated regions and black regions indicating coding sequences. Vertical lines indicate site of called
nonsynonymous single nucleotide variant, and only the recurrent mutations were annotated. (D) As in (C), with representative regions of inter-
est in the HRAS oncogene highlighting recurrent mutation sites presented in schematic as shown, suggesting the majority of HRAS mutant
patients would be detected with probes covering G12, G13, and Q61. ctDNA = circulating tumor DNA; HNSCC = head and neck squamous
cell carcinoma; HPV = human papillomavirus. [Color figure can be viewed in the online issue, which is available at www.laryngoscope.com.]
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clinical utility of EBV DNA as a prognostic biomarker
still needs to validated in prospective clinical trials.
Techniques for Analyzing ctDNA
Recent advancements in single molecule-based NGS
technology, coupled with improvements in bioinformatics
approaches, have enabled the ability to genotype cancer
patients in real time from minimal amounts of ctDNA. In
fact, several different techniques have recently been
developed to detect and quantify ctDNA in a variety of
cancer settings, which can be broadly divided into three
main types of assay based on the intent to detect either
early stage cancer, changes to molecular pathways driv-
ing tumor evolution, and response to therapy or evidence
for early recurrence of an already genotyped cancer.
Early detection assays that attempt to discover uni-
dentified cancers are perhaps the most technically chal-
lenging because they require highly sensitive methods
that assess broad spectrums of the most probable patho-
genic alterations. The primary challenge of these assays
is the ability to differentiate between somatic events and
alterations from either the normal germline or those that
occur during hematopoietic cell proliferation,55 which are
generally thought to require a high depth of sequencing
coverage and comprehensive databases of germline and
hematopoietic alterations. Due to current limitations in
the number of genes that can be cost-effectively
sequenced to appropriate depth for high confidence anno-
tation, early detection ctDNA assays tend to rely on
panel-based approaches to identify 50 to 100 common
genetic alterations found in either an individual cancer or
a small set of genetically related cancers.36,56,57
For cancers driven by a relatively small set of con-
sensus drivers, early detection assays have the advantage
of having to sequence smaller gene sets; in contrast, for
cancers such as HNSCC, which are known to have a large
and diverse number of oncogenic drivers.58–60 The detec-
tion of early diagnosis panels becomes slightly more chal-
lenging because the number of alterations observed
across large multi-exon genes, such as TP53 or NOTCH1,
requires significantly more probes and sequencing cover-
age than oncogenes with “hotspot” molecular alterations
occurring at only a few nucleotides in genes, such as
HRAS and PIK3CA (Fig. 2).
To overcome these types of challenges, Phallen
et al. recently developed a technique called targeted error
correction-SEQ, which examines 58 cancer-related genes
and uses optimized sequencing and bioinformatics
methods to reduce the overall potential of amplification,
sequencing, and contamination errors.6 Using this
method, the authors were about to detect stage 1 or 2 dis-
ease in 59% to 71% of patients with colorectal, breast,
lung, or ovarian cancers representing a large improve-
ment in the ability to detect malignancies. Although this
method has not been applied to a large population of
patients, it will be interesting to determine the predictive
value of the assay for each population.
In contrast to these complex assays to detect early
disease or genetic evolution, the assays developed to
detect early recurrence have mostly focused on the
tracing individual lesions. The rationale for this approach
is based on heterogeneity lineage tracing experiments
from several different cancer types, suggesting that once
a driver lesion occurs in a tumor, it can often be traced in
subclones recurring either locally or distantly.61–65 In the
case of HPV+ HNSCC or mucoepidermoid carcinoma, the
development of methods to individually monitor high-risk
HPV DNA or CRTC1/3-MAML2 gene fusions, respec-
tively, represents a straightforward approach to develop
assays with high specificity for detection.66,67 Conse-
quently, once the tumor specific primary lesion has been
characterized and likely driver alterations are identified,
individualized assays can be developed to trace likely
driver lesions. Several examples have emerged in litera-
ture that leverage quantitative PCR, RT-PCR, digital
droplet PCR, and/or NGS.68–70 This method has been
especially useful for monitoring recurrence in cancers
that are defined by highly recurrent “hotspot” mutations
such as BRAF V600E in melanoma; however, even these
studies have also shown limits in sensitivity suggesting
that monitoring for additional loci may provide an oppor-
tunity to improve overall assay performance.
Future Applications of ctDNA in Head and Neck
Cancer
Direct tumor sequencing and mutation detection in
plasma cfDNA are unlikely to be a viable clinical
approach due to the associated complexity and turn-
around time.36 However, as previously discussed based
on the known mutational landscape of HNSCC, a ctDNA
panel could be designed to detect and monitor cases in a
rapid and cost-effective fashion.33 Use of such a panel
would enable researchers and clinicians to detect and
monitor non-HPV–related malignancies, which still con-
stitute the majority of HNSCC cases. This would allow
trials of previously untreated locally advanced HNSCC to
move beyond risk stratification by tumor-node-metastasis
stage or HPV status and instead move to real-time
response of tumors to therapy as judged by ctDNA
dynamics. That could drive intensification of therapy in
patients with lack of disease response via ctDNA or de-
escalatation of therapy based on a fall in ctDNA, thereby
preventing treatment-related toxicity. Before either of
these designs is pursued, we need not only a validated
biomarker test but also an understanding of normal
biomarker dynamics during treatment to identify
responders/nonresponders.
Development of novel therapeutics in unresectable
recurrent or metastatic HNSCC has been met with little
success. Cytotoxic chemotherapy can cause severe adverse
effects without significant meaningful response, limiting its
use and the ability to receive further therapy. Although
promising, immunotherapy has been found to have a low
response rate of 13%, which is often not appreciated for sev-
eral months.71–73 Novel methods of detecting response are
needed to better establish response to therapy and avoid
exposure to toxic, ineffective agents. A ctDNA biomarker
panel test could detect response prior to traditional radio-
graphic imaging. Analogous to past breast cancer trials,74 if
a biomarker is able to be validated as predicting response
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prior to conventional imaging (i.e., blood draw after 1 cycle
vs. imaging after 3 cycles), a trial evaluating early switch of
therapy in those nonresponsive to therapy is quite enticing.
Such a trial has the potential to spare patients the toxicities
of ineffective therapy and more rapidly administer benefi-
cial therapies. Even more revolutionary would be evaluation
of whether clonal resistance can be detected via a ctDNA
panel and whether modification of therapy based on clonal
resistance would alter patient outcomes. This scenario
would take much more development, advancement of bioin-
formatics, and likely effective targeted therapies.
CONCLUSION
Although several questions remain, including the
cost-effectiveness of in-depth sequencing and improving
the speed at which sequencing results are obtained, early
studies published thus far have demonstrated promising
results for implementing ctDNA monitoring into clinical
care. If ctDNA monitoring proves truly impactful, it may
not only make routine assessments of cancer progression
and response to therapy cheaper and accessible but may
also lead to significant improvements in early detection.
In addition, we may begin to observe improvements in
overall survival for patients with this difficult-to-monitor
disease.
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